Search the Newsreel

Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes

Frazier Life Sciences Public Fund, L.P. has reported a 5.6% ownership stake in Allogene Therapeutics (ALLO), holding 19,445,046 shares. Other affiliated Frazier funds also hold additional stakes, bringing the total reported beneficial ownership by various Frazier entities and individuals to a significant portion of …

Earnings Flash (ALOY) REalloys Inc. Reports Q2 Revenue $0.8M, vs. FactSet Est of $0.7M

REalloys Inc. (ALOY) reported its Q2 revenue at $0.8 million, surpassing FactSet's estimate of $0.7 million. This announcement comes amid other recent company news, including a wider Q2 loss and strategic movements to develop a North American rare earth magnet platform. The company is …

Allogene Therapeutics (ALLO) Income Statement & Earnings

Allot Ltd. (ALLT) schedules potential Rule 144 sale of 26,666 Ordinary Shares

Allot Ltd. (ALLT) has filed a Form 144 with the SEC, indicating a potential sale of up to 26,666 Ordinary Shares through Oppenheimer & Co. Inc. on the Nasdaq. The aggregate value of these shares is approximately $211,461.38, and they originate from two RSU …

ALICON: Record sales, robust order book, and margin expansion targeted amid strong industry growth

Alicon Castallo Q1 Results FY27: Revenue Rs 578 crore, PAT Rs 11 Crore

ALICON: Record sales, strong order book, and capacity expansion drive growth amid margin pressures

Maithan Alloys Q1 Results FY27: PAT Rs 395 Cr, Revenue Rs 539 crore

Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

The FDA has granted RMAT and Fast Track designations to Allogene's TALEN-edited, allogeneic CD19 CAR T-cell therapy, cema-cel, for first-line consolidation in large B-cell lymphoma. An interim analysis showed cema-cel cleared minimal residual disease in a significant proportion of patients, with no serious adverse …

Earnings call transcript: Alicon Castalloy posts record Q1 2026 sales

Alicon Castalloy consolidated net profit rises 22.99% in the June 2026 quarter

Allot (ALLT) Stock Finds Support As SECaaS Growth Fuels Profitability

Price to earnings forward of Xingye Alloy Materials Group Limited – HKEX:505

Form 8K REalloys Inc For: 13 August By Investing.com

This article from Investing.com is a simple notification about an 8K filing by REalloys Inc. for August 13th. The main content of the article is limited to the headline and a repetition of the filing information, with no further details provided within the body. …

REalloys Inc. (NASDAQ: ALOY) widens loss to $143.5M but lifts cash to $122M

REalloys Inc. (NASDAQ: ALOY) reported a net loss of $143.5 million for the first half of 2026, significantly wider than the $3.9 million loss a year prior, primarily due to heavy operating expenses and $113.9 million in stock-based compensation. Despite the increased loss, the …

REalloys Reports Second Quarter 2026 Results

REalloys Inc. reported its second-quarter 2026 results, highlighting significant progress in fully funding the upgrade of the Saskatchewan Research Council (SRC) Rare Earth Processing Facility and its Heavy Rare Earth Metallization Facility. The company ended the quarter with $122.4 million in cash after closing …

REALLOYS INC. 2026: Revenue $804K, EPS ($0.59) — 10-Q Summary

REALLOYS INC. (ALOY) reported its 2026 quarterly results with revenue of $804K, an 82.7% year-over-year increase, but a net loss of ($36.82M) and a diluted loss per share of ($0.59). Revenue growth was attributed to metal sales, subscription income, and strategic initiatives like a …

Allot (NASDAQ:ALLT) Posts Quarterly Earnings Results

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported a narrower-than-expected Q2 2026 loss of 13 cents per share, beating the Zacks Consensus Estimate of 16 cents, primarily due to lower research and development costs. The company's cash position extended its runway into 2029, and it is progressing with …

BlackRock ESG Capital Allocation (ECAT): Saba Capital discloses 14.75% ownership stake

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

RBC Capital Markets reiterated that Allogene Therapeutics remains an attractive investment due to its appealing valuation and distinctive clinical strategy. The company highlighted a 41% improvement in minimal residual disease on the large B-cell lymphoma front. Access to the full analysis requires a premium …

ALICON: Record revenue and strong order book drive growth despite margin pressures from input costs

Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL

Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel) is being evaluated in ALPHA3, a pivotal Phase 2 trial for high-risk Large B-Cell Lymphoma (LBCL) patients. The trial aims to assess if MRD-guided treatment can delay or prevent relapse, with early data showing favorable MRD negativity …

Price to book forward of BlackRock Capital Allocation Term Trust – NYSE:BCAT

This article provides financial information for BlackRock Capital Allocation Term Trust (NYSE: BCAT), specifically focusing on its "Price to book forward" metric. The content appears to be a financial data page from TradingView, offering an overview of BCAT's financials, news, and other market data. …

ALICON: Strong revenue and profit growth, board changes, and a final dividend of Rs.3 per share

Alicon Castalloy Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Shah Alloys Q1 Results: Net loss narrows to ₹2.07 crore as revenue falls 99%

722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. has acquired a new position of 722,928 shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO), valued at approximately $1.5 million. This purchase gives the firm a 0.21% stake in the company, contributing to the 83.63% institutional ownership of Allogene. The …

Ascent Industries Co. $ACNT Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its stake in Ascent Industries Co. by 23.4% in the first quarter, selling 86,623 shares and retaining 283,567 shares valued at approximately $3.77 million. Several other institutional investors also adjusted their positions in the company, with institutional investors and …

REalloys (ALOY) Earnings Date and Reports 2026 $ALOY

Allot Ltd. Q2 2026 Earnings Call Summary

Allot Ltd. reported a strong Q2 2026, achieving its fourth consecutive quarter of double-digit growth, primarily driven by North American sales and its Cybersecurity as a Service (SECaaS) business. The company raised its 2026 revenue guidance to $115 million–$118 million and announced a $40 …

Shah Alloys reports standalone net loss of Rs 2.07 crore in the June 2026 quarter

Gross margin % of BlackRock Capital Allocation Term Trust – FWB:BD8

This article displays the gross margin percentage for BlackRock Capital Allocation Term Trust (FWB:BD8) on the TradingView platform. The content is primarily a data page showing financial metrics for the investment trust, indicating no specific values but rather a placeholder for financial data.